Haleon plc Form 6-K Summary
Business context and reporting period
This Form 6-K, filed for July 2022, reports the completion of the demerger of GSK’s Consumer Healthcare business to form Haleon Group. It includes announcements dated July 18, 2022 concerning the admission of Haleon shares, total voting rights, and major shareholdings.
Haleon is a global consumer-health company operating in approximately 170 markets with more than 22,000 employees. Its principal categories are oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements.
Key financial and capital metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial results.
- 9,234,573,831 ordinary shares were issued and admitted to trading, with one vote per share and no shares held in treasury.
- Ordinary shares had a nominal value of £1.25 each, subject to a planned capital reduction to 1 pence per share.
- Haleon also had 25,000,000 fully paid, non-voting preference shares, which were not listed.
- Each Haleon American Depositary Share represents two ordinary shares.
Material changes versus the prior comparable period
- The principal change was the legal and capital-market separation of Haleon from the GSK Group; the filing does not present a comparable prior-period income statement or balance-sheet analysis.
- Haleon ordinary shares began trading on the London Stock Exchange’s premium listing segment and main market at 8:00 a.m. on July 18, 2022.
- Haleon ADSs were expected to begin when-issued trading on the NYSE on July 18 and regular-way trading on July 22, 2022.
- GSK and related entities reported 1,195,320,110 Haleon voting rights, equal to 12.94% of voting rights, held directly and indirectly through Vidacos Nominees Limited.
- Berkeley Square Pension Trustee Company Limited reported 602,094,214 voting rights, equal to 6.52%, held indirectly through GSK-related Scottish limited partnerships.
Guidance, outlook, risks and unusual items
- No quantitative financial guidance or earnings outlook is provided in the filing.
- The stated timetable for listings, share certificates, and account credits is indicative and may change. Certain dates are subject to the timing of the capital reduction.
- Haleon cautions that forward-looking statements are subject to economic and business conditions, consumer-health market risks, regulation, competition, technology, inflation, foreign-exchange movements, acquisitions or divestments, taxation, legislation, and other factors.
- The demerger, capital reduction, new listings, and post-separation ownership structure are the principal unusual and transaction-related items.
Important facts for investors to verify
- Completion and terms of Haleon’s capital reduction from £1.25 to 1 pence per ordinary share.
- The final share count, voting-rights denominator, and any subsequent treasury-share activity.
- Commencement and continued trading status of Haleon ordinary shares and ADSs on the LSE and NYSE.
- Haleon’s first standalone financial statements, including revenue, profitability, cash flow, debt, liquidity, margins, and dividend policy.
- Changes in GSK’s and other major holders’ ownership after the demerger.
- Transaction-related obligations, separation costs, contingencies, and other risks described in Haleon’s Prospectus and Form 20-F risk factors.